Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CarPal Head and Neck: Palbociclib and Carboplatin in Metastatic HNSCC
NCT03194373Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2017
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Disease Control Rate at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
palbociclib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03194373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194373.